The UPs and DOWNs of MITF in melanoma resistance

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pigment Cell & Melanoma Research

• Publication date

  2015-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/pcmr.12338PMID 25476804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.

  2015cited by this paper
• MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines

  2014cited by this paper
• A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

  2013cited by this paper
• Directed phenotype switching as an effective antimelanoma strategy.

  2013cited by this paper
• Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

  2013cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Cancer stem cells versus phenotype‐switching in melanoma

  2010cited by this paper

• Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation

  2015cites this paper